BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...SIX:ROG; OTCQX:RHHBY), and Afinitor everolimus and Tykerb lapatinib...
BioCentury | Jan 28, 2020
Distillery Therapeutics

Inhibiting CD36 to overcome resistance to Tykerb in HER2-positive breast cancer

...a fatty acid transporter, could treat HER2-positive breast cancer and sensitize tumors resistant to Tykerb lapatinib...
...cells and a CD36 inhibitor tool compound sensitized the cells to Tyverb. In mice with Tykerb-resistant...
...Kurokawa, Dartmouth College, Hanover, N.H.; Kent State University, Kent, Ohio email: mkurokaw@kent.edu Claire Quang Tykerb, Tyverb, lapatinib (GW572016) Dartmouth...
BioCentury | Dec 11, 2019
Clinical News

AstraZeneca, Daiichi’s trastuzumab ADC sets new efficacy bar in breast cancer

...data for Kadcyla. In EMILIA, Kadcyla posted an ORR of 43.6% vs. 30.8% for Tykerb lapatinib...
...lapatinib plus capecitabine and a median PFS of 9.6 months vs. 6.4 months for the Tykerb...
BioCentury | Oct 21, 2019
Clinical News

Seattle Genetics at all-time high on strength of breast cancer readout

...is poised to see an influx of targeted treatments in the next few years. Tykerb lapatinib...
BioCentury | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

...models. In additional PDX models, the DHODH inhibitor Aubagio teriflunomide in combination with either Tykerb lapatinib...
...leukemia (AML) and Phase I testing for solid tumors. Novartis AG and Eddingpharm Inc. market Tykerb...
...of California San Diego, La Jolla, Calif. email: drjeremyrich@gmail.com Claire Quang Aubagio, teriflunomide (HMR1726) buparlisib (BKM120) Tykerb, Tyverb, lapatinib (GW572016) University...
BioCentury | May 16, 2019
Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

...progression or death by 24% (p=0.006) and non-significantly improved survival by 12% (p=0.2086) vs. Tykerb lapatinib...
BioCentury | Apr 18, 2019
Distillery Techniques

Patient cell-derived, 3-D model of PDAC and tumor microenvironment

...create motion that recapitulates the fluid dynamics of an active tumor microenvironment. In the model, lapatinib...
BioCentury | Sep 14, 2018
Company News

ACS’s Brawley disappointed in Baselga resignation

...pertuzumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), and Afinitor everolimus and Tykerb lapatinib...
BioCentury | Aug 31, 2018
Clinical News

China approves Hengrui breast cancer drug on Phase II data

...survival (PFS) of 18.1 months vs. 57.1% and 7 months (HR=0.363, p<0.0001), respectively, for Tykerb lapatinib...
BioCentury | Aug 22, 2018
Company News

China approves Hengrui breast cancer drug on Phase II data

...survival (PFS) of 18.1 months vs. 57.1% and 7 months (HR=0.363, p<0.0001), respectively, for Tykerb lapatinib...
Items per page:
1 - 10 of 242